Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > PARP Inhibitors May Have Clinical… >
PARP Inhibitors May Have Clinical Utility in HER2-positive Breast Cancers

Published: September 17, 2012.
By American Association for Cancer Research
http://www.aacr.org

PHILADELPHIA — Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

Currently, women with HER2-positive breast cancers are treated with therapies that target HER2. However, many women with this form of cancer either fail to ever respond to these targeted therapies or initially respond to them but then become resistant to their effects.

"Until now, PARP inhibitors have been shown to exhibit single agent activity only in tumors that are deficient in DNA repair, such as familial breast and ovarian cancers that are linked to BRCA mutations," said Eddy S. Yang, M.D., Ph.D., assistant professor in the department of radiation oncology at the University of Alabama-Birmingham.

According to Yang, only about 5 to 10 percent of all breast and ovarian cancers are BRCA-associated familial cancers, so researchers are currently trying to expand the patient population that might benefit from PARP inhibitors, which are generally well tolerated and have relatively few side effects.

"To do that, we were attempting to render nonfamilial cancers deficient in DNA repair," he said.

In prior studies, the Yang lab found that inhibiting the epidermal growth factor receptor (EGFR) pathway, which is commonly overactive in many tumor types, resulted in a DNA repair defect similar to that seen in familial cancers. They subsequently showed that this "forced" DNA repair defect increased tumor sensitivity to PARP inhibitors. Because HER2 and EGFR are in the same family of proteins, Yang and colleagues theorized that HER2-targeted therapies might force a similar DNA repair defect in HER2-positive tumors, increasing their sensitivity to PARP inhibitors.

They found that HER2-positive breast cancer cell lines were indeed sensitive to PARP inhibitors, both in culture and when transplanted into mice.

"However, the surprise was that these HER2-positive tumors were sensitive to PARP inhibitors alone, independent of a DNA repair defect," Yang said. "This means that there may be other mechanisms, outside of DNA repair, that dictate the sensitivity of a tumor to PARP inhibitors."

The researchers hope to further map out the reason why HER2-positive tumors are sensitive to PARP inhibitors. If better defined, the knowledge could ultimately broaden the clinical application for PARP inhibitors.

"Our research suggested that inhibition of NF-kB signaling is a possible cause of this sensitivity, but there may be other determinants as well," Yang said. "If we are able to find the determinants of sensitivity, we may be able to extrapolate our effects to other tumor types."


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Cancer 
7/9/11 
★ 
Targeted Agent Addition to Herceptin Has Positive Effect on Metastatic HER-2 Breast Cancer
By University of Texas M. D. Anderson Cancer Center
Houston - Adding Afinitor to Herceptin¬ the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a …
Treatment 
12/11/13 
Study Identifies Highly Effective Treatment Option for Patients with HER2-positive Breast Cancer
By American Association for Cancer Research
SAN ANTONIO — Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast …
Levels 
1/24/13 
Treatment Targeting PI3K May Delay Resistance to Anti-HER2 Therapy in Breast Cancer Patients
By American Association for Cancer Research
PHILADELPHIA — Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 …
Results 
6/2/14 
ALTTO Test of Dual HER2 Blockade Finds Single Agent Remains the Gold Standard
By Mayo Clinic
CHICAGO — June 1, 2014 — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add …
Tumors 
1/17/14 
★★★ 
VHIO Genomic Study Identifies Subgroups of HER2+ Breast Cancer with Varying Sensitivities
By Vall d´Hebron Institute of Oncology
Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four …
Herceptin 
10/6/11 
Survival Increased in Early Stage Breast Cancer After Treatment with Herceptin And Chemo
By University of California - Los Angeles Health Sciences
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that …
Breast 
3/26/10 
Survival in Metastatic Breast Cancer Patients Is Improving: Targeted Therapies Have Contributed
By ECCO-the European CanCer Organisation
Barcelona, Spain: Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor …
Fan 
11/15/10 
★ 
Erythropoietin Counteracts Breast Cancer Treatment with Herceptin
By University of Texas M. D. Anderson Cancer Center
HOUSTON - Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of …
Cancer 
5/21/14 

Team Validates Potentially Powerful New Way to Treat HER2-positive Breast Cancer
By Cold Spring Harbor Laboratory
Nelfinavir 
10/5/12 
HIV Drug Shows Efficacy in Treating Mouse Models of HER2+ Breast Cancer
By Journal of the National Cancer Institute
The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition